U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H36N2O11
Molecular Weight 612.6243
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NOVOBIOCIN

SMILES

CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3C(O)=C(NC(=O)C4=CC(CC=C(C)C)=C(O)C=C4)C(=O)OC3=C2C)OC1(C)C

InChI

InChIKey=YJQPYGGHQPGBLI-KGSXXDOSSA-N
InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1

HIDE SMILES / InChI

Molecular Formula C31H36N2O11
Molecular Weight 612.6243
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.federalregister.gov/documents/2011/01/19/2011-1000/determination-that-albamycin-novobiocin-sodium-capsule-250-milligrams-was-withdrawn-from-sale-for | https://www.ncbi.nlm.nih.gov/pubmed/3036023

Novobiocin (also known as streptonivicin) is an aminocoumarin antibiotic, active against Staphylococcus epidermidis. Novobiocin and other aminocoumarin antibiotics act as a potent competitive inhibitor of DNA gyrase B. The oral form of the drug was withdrawn from the market in 1999 due to safety or effectiveness reasons. Later it was discovered that novobiocin inhibited Hsp90 and topoisomerase II, and novobiocin was investigated in clinical trials against metastatic breast cancer and non-small cell lung cancer. Topical form of novobiocin was investigated in combination with nalidixic acid for treatment of psoriasis.

Originator

Curator's Comment: Novobiocin is the generic name that has been adopted for two new antibiotics which were discovered independently of each other and later found to be identical. One of these, Cathomycin, a product of Upjohn Company, is derived by from Streptomyces spheroides n. sp., and the other, streptonivicin, is derived from Streptomyces niveus by Pfizer. # Pfizer, Upjohn Company

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL1795086
Target ID: Q5HK03
Gene ID: NA
Gene Symbol: gyrB
Target Organism: Staphylococcus epidermidis (strain ATCC 35984 / RP62A)
0.9 µM [IC50]
300.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ALBAMYCIN

Approved Use

Treatment of serious infections due to susceptible strains of Staphylococcus aureus when other less toxic antibiotics such as the penicillins, cephalosporins, vancomycin, lincomycin, erythromycin, and the tetracyclines cannot be used.

Launch Date

-1.68048001E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Curative
ALBADRY PLUS

Approved Use

ALBADRY PLUS Suspension is indicated for the treatment, in dry cows only, of subclinical mastitis caused by susceptible strains of Staphylococcus aureus and Streptococcus agalactiae.

Launch Date

4.10745602E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.5 μg/mL
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NOVOBIOCIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
407 μg × h/mL
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NOVOBIOCIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.85 h
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NOVOBIOCIN serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
unknown, unknown
NOVOBIOCIN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 1 times / day steady, oral
Dose: 2 g, 1 times / day
Route: oral
Route: steady
Dose: 2 g, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M
Sources:
Other AEs: Jaundice...
Other AEs:
Jaundice (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Jaundice 1 patient
2 g 1 times / day steady, oral
Dose: 2 g, 1 times / day
Route: oral
Route: steady
Dose: 2 g, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Clinical effectiveness and safety of novobiocin.
1956 Apr
Screening for new compounds with antiherpes activity.
1984 Oct
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
1988 Feb
In vitro activity of DNA gyrase inhibitors, singly and in combination, against Mycobacterium avium complex.
1992 May-Jun
Drug-sensing hydrogels for the inducible release of biopharmaceuticals.
2008 Oct
Responsive hydrogels for label-free signal transduction within biosensors.
2010
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.
2011 Aug
Patents

Sample Use Guides

As antibiotic, novobiocin was marketed in 250 mg capsules and administered orally. For the treatment of psoriasis, novobiocin (2% or 5%) in methylcellulose were applied twice daily under occlusion.
Route of Administration: Other
Minimal inhibitory concentration of novobiocin against a panel of microorganisms were determined by using the broth microdilution procedure recommended by the National Committee for Clinical Laboratory Standards.Microtiter plates (96 wells/plate; final assay volume, 100 μl per well) were inoculated with exponential-phase cells and incubated overnight at 35°C in ambient air. Wells were examined for bacterial growth by using an illuminated microtiter plate reader fitted with a magnifying mirror. MIC for Staphylococcus aureus was <= 0.06 ug/ml.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:30:26 UTC 2023
Edited
by admin
on Wed Jul 05 22:30:26 UTC 2023
Record UNII
17EC19951N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NOVOBIOCIN
GREEN BOOK   HSDB   INN   MART.   MI   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
BENZAMIDE, N-(7-((3-O-(AMINOCARBONYL)-6-DEOXY-5-C-METHYL-4-O-METHYL-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-4-HYDROXY-8-METHYL-2-OXO-2H-1-BENZOPYRAN-3-YL)-4-HYDROXY-3-(3-METHYL-2-BUTEN-1-YL)-
Common Name English
NOVOBIOCIN [GREEN BOOK]
Common Name English
NOVOBIOCIN [HSDB]
Common Name English
BENZAMIDE, N-(7-((3-O-(AMINOCARBONYL)-6-DEOXY-5-C-METHYL-4-O-METHYL-.BETA.-L-LYXO-HEXOPYRANOSYL)OXY)-4-HYDROXY-8-METHYL-2-OXO-2H-1-BENZOPYRAN-3-YL)-4-HYDROXY-3-(3-METHYL-2-BUTENYL)-
Common Name English
Novobiocin [WHO-DD]
Common Name English
NOVOBIOCIN [MI]
Common Name English
NOVOBIOCIN [USP-RS]
Common Name English
novobiocin [INN]
Common Name English
NOVOBIOCIN [VANDF]
Common Name English
NOVOBIOCIN [MART.]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01XX95
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
CFR 21 CFR 526.1696D
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
CFR 21 CFR 526.1590
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
NCI_THESAURUS C258
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
CFR 21 CFR 558.415
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
CFR 21 CFR 556.460
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
Code System Code Type Description
PUBCHEM
54675769
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
CHEBI
28368
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
MERCK INDEX
M8081
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY Merck Index
RXCUI
7538
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY RxNorm
EVMPD
SUB09385MIG
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
ECHA (EC/EINECS)
206-146-3
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
DRUG BANK
DB01051
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
CHEBI
71339
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
HSDB
7443
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
MESH
D009675
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
FDA UNII
17EC19951N
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
SMS_ID
100000083605
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID3041083
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
DRUG CENTRAL
1974
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
WIKIPEDIA
NOVOBIOCIN
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
DAILYMED
17EC19951N
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
INN
575
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
ChEMBL
CHEMBL36506
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
NCI_THESAURUS
C705
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
RS_ITEM_NUM
1475008
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
CAS
303-81-1
Created by admin on Wed Jul 05 22:30:26 UTC 2023 , Edited by admin on Wed Jul 05 22:30:26 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY